Valereum PLC - $10 million Funding Facility with US led Syndicate
Released
Released
Announcement PDF
RNS Number : 1618A
Valereum PLC
31 January 2022
The information contained within this announcement is deemed by the Company to constitute
inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it
forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR")
31 st January 2022
Valereum Plc
("Valereum" or the "Company")
$10 million Funding Facility with US led Syndicate
Valereum is pleased to announce that it has drawn US$3m from a new
US$10m investment facility provided by a syndicate of institutional investors
led by a US managed institutional investor. These funds will be used to
advance Valereum's acquisition of the Gibraltar Stock Exchange ("GSX"). This
will enable the previously announced strategy to be put in place.
Richard Poulden, Chairman of Valereum commented: "It is great to
have international institutional support for our projects in Gibraltar."
This US$3m tranche has a six-month term (the "term"), after which the facility
can be repaid or extended at Valereum's option.
Outstanding principal amounts may be converted into ordinary shares at
£0.3682 during the term. After six months, if extended, conversion may
occur at that price or, if lower, at a 5% discount to the then current 10 day
lowest daily VWAP.
This drawing carries 663,302 two-year warrants at £0.3347.
The Directors of the Company accept responsibility for the contents of this
announcement.
END
Enquiries:
Valereum Plc
Richard Poulden, Chairman
Tel: +971 4584 6284
AQSE Corporate Adviser
Peterhouse Capital Limited
Tel: +44 (0) 207 469 0930
Investor Relations
J&H Communications Limited
James Henderson
Tel: +44 (0)7774 444163
james@j-hcommunications.com
George Hudson
Tel: +44 (0)7803 603130
george@j-hcommunications.com
For more information, please visit the Company's website at valereum.gi
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the
Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions
relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with
the information contained in this communication, and to share such analysis on an anonymised basis with others as
part of our commercial services. For further information about how RNS and the London Stock Exchange use the
personal data you provide us, please see our Privacy Policy.
END
NEXBKDBBDBKDQDN
Share your feedback
Discover